Comparative Atorvastatin Pleiotropic Effects
CAP
A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis
1 other identifier
interventional
330
7 countries
74
Brief Summary
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Jun 2002
Typical duration for phase_4
74 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 9, 2005
CompletedFirst Posted
Study publicly available on registry
September 13, 2005
CompletedFebruary 18, 2021
February 1, 2021
September 9, 2005
February 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Percentages changes of the hs-CRP between baseline (means between week-2 to -1 and week 0 (V2) values) and week 26 (V5).
Secondary Outcomes (1)
1/ the percentage change at visit 3 (5-week treatment), visit 4 (13-week-treatment) and visit 5 (26-week treatment) from baseline value in triglycerides, total cholesterol; HDL-cholesterol, LDL-cholesterol, apolipoprotein B 2/ the percentage change at
Interventions
Eligibility Criteria
You may qualify if:
- Male or female subjects of age of majority to \< 80 years
- Subjects with LDL-C \> 0.5 g/L (1.29 mmol/L) and \< 1.5 g/L (3.87 mmol/L), TG \< 4.00 g/L (4.56 mmol/L) and hs-CRP \>1.5 mg/L and \< 15 mg/L
- Subjects with a documented coronary artery disease.
You may not qualify if:
- Female subjects of childbearing potential without contraception
- Subjects with secondary hyperlipidemia
- Diabetic subjects receiving insulin
- Subjects with a contra-indication to statin therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (74)
Pfizer Investigational Site
Calgary, Alberta, T2E 7C5, Canada
Pfizer Investigational Site
Edmonton, Alberta, T6G 2S2, Canada
Pfizer Investigational Site
Vancouver, British Columbia, v6z 1y6, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, R3E 0Z3, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 2Y9, Canada
Pfizer Investigational Site
London, Ontario, N6G 2V2, Canada
Pfizer Investigational Site
Oshawa, Ontario, L1J 2K1, Canada
Pfizer Investigational Site
Sarnia, Ontario, N7T 4X3, Canada
Pfizer Investigational Site
Toronto, Ontario, M5C 2T2, Canada
Pfizer Investigational Site
Weston, Ontario, M9N 1W4, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, G7H 5H6, Canada
Pfizer Investigational Site
Laval, Quebec, H7V 2T8, Canada
Pfizer Investigational Site
Montreal, Quebec, H1T 1C8, Canada
Pfizer Investigational Site
Montreal, Quebec, H1T 2M4, Canada
Pfizer Investigational Site
Montreal, Quebec, H2W 1R7, Canada
Pfizer Investigational Site
Montreal, Quebec, H4J 1C5, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 5N4, Canada
Pfizer Investigational Site
Ste-foy, Quebec, G1V 4G2, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7N 0W8, Canada
Pfizer Investigational Site
Brno-Bohunice, 63900, Czechia
Pfizer Investigational Site
Jindřichův Hradec, 377 38, Czechia
Pfizer Investigational Site
Prague, 120 00, Czechia
Pfizer Investigational Site
Prague, 128 08, Czechia
Pfizer Investigational Site
Prague, 150 06, Czechia
Pfizer Investigational Site
Clermont-Ferrand, Cedex, 63003, France
Pfizer Investigational Site
Langres, Cedex, 52206, France
Pfizer Investigational Site
Besançon, 25030, France
Pfizer Investigational Site
Brest, 29609, France
Pfizer Investigational Site
Chambéry, 73000, France
Pfizer Investigational Site
Clamart, 92141, France
Pfizer Investigational Site
Clermont-Ferrand, 63003, France
Pfizer Investigational Site
Creil, 60100, France
Pfizer Investigational Site
Dijon, 21034, France
Pfizer Investigational Site
Évecquemont, 78740, France
Pfizer Investigational Site
Gap, 05000, France
Pfizer Investigational Site
Hénin-Beaumont, 62256, France
Pfizer Investigational Site
Le Kremlin-Bicêtre, 94275, France
Pfizer Investigational Site
Lille, 59037, France
Pfizer Investigational Site
Marseille, 13385, France
Pfizer Investigational Site
Metz, 57038, France
Pfizer Investigational Site
Monaco, 98000, France
Pfizer Investigational Site
Montpellier, 34295, France
Pfizer Investigational Site
Mulhouse, 68070, France
Pfizer Investigational Site
Nancy, 54000, France
Pfizer Investigational Site
Nantes Saint Herblain, 44805, France
Pfizer Investigational Site
Paris, 75015, France
Pfizer Investigational Site
Paris, 75018, France
Pfizer Investigational Site
Paris, 75230, France
Pfizer Investigational Site
Paris, 75877, France
Pfizer Investigational Site
Paris, 75908, France
Pfizer Investigational Site
Pessac, 33064, France
Pfizer Investigational Site
Poissy, 78303, France
Pfizer Investigational Site
Pontoise, 95300, France
Pfizer Investigational Site
Roubaix, 59056, France
Pfizer Investigational Site
Saint-Michel, 16470, France
Pfizer Investigational Site
Thionville, 57100, France
Pfizer Investigational Site
Toulouse, 31403, France
Pfizer Investigational Site
Tourcoing, 59200, France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, 54500, France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, 54511, France
Pfizer Investigational Site
Bełchatów, 97-400, Poland
Pfizer Investigational Site
Gdynia, 81-472, Poland
Pfizer Investigational Site
Rawa Mazowiecka, 96-200, Poland
Pfizer Investigational Site
Torun, 87-100, Poland
Pfizer Investigational Site
Wroclaw, 50-420, Poland
Pfizer Investigational Site
Zamość, 22-400, Poland
Pfizer Investigational Site
Bucharest, Sector 2, 70000, Romania
Pfizer Investigational Site
Bucharest, Sector 2, 7000, Romania
Pfizer Investigational Site
Bucharest, Sector 5, 76251, Romania
Pfizer Investigational Site
Moscow, 101953, Russia
Pfizer Investigational Site
Moscow, 121552, Russia
Pfizer Investigational Site
Volgograd, 400008, Russia
Pfizer Investigational Site
Bratislava, 81369, Slovakia
Pfizer Investigational Site
Bratislava, 83348, Slovakia
Related Publications (1)
Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.
PMID: 19167589DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 9, 2005
First Posted
September 13, 2005
Study Start
June 1, 2002
Study Completion
August 1, 2005
Last Updated
February 18, 2021
Record last verified: 2021-02